<code id='F34F2A053D'></code><style id='F34F2A053D'></style>
    • <acronym id='F34F2A053D'></acronym>
      <center id='F34F2A053D'><center id='F34F2A053D'><tfoot id='F34F2A053D'></tfoot></center><abbr id='F34F2A053D'><dir id='F34F2A053D'><tfoot id='F34F2A053D'></tfoot><noframes id='F34F2A053D'>

    • <optgroup id='F34F2A053D'><strike id='F34F2A053D'><sup id='F34F2A053D'></sup></strike><code id='F34F2A053D'></code></optgroup>
        1. <b id='F34F2A053D'><label id='F34F2A053D'><select id='F34F2A053D'><dt id='F34F2A053D'><span id='F34F2A053D'></span></dt></select></label></b><u id='F34F2A053D'></u>
          <i id='F34F2A053D'><strike id='F34F2A053D'><tt id='F34F2A053D'><pre id='F34F2A053D'></pre></tt></strike></i>

          focus

          focus

          author:comprehensive    Page View:87
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

          A Worst CEO gets some much-needed help

          For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

          advertisement

          On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway
          Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

          3:04PeoplegatheraroundandcheerforKaiCenat,center,asmembersoftheNYPDrespondtothousandsofpeoplegathere

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

          Bayer'sU.S.president,SebastianGuth,emphasizedataninterviewattheSTATofficesinBostonthatthepharmacompa